D espite using normal speech (usually at home), children with SM fail to speak in selective environments (often at school). 1 Treatment of this potentially debilitating condition has received limited research attention, partly owing to its rarity (prevalence is estimated at 0.7% 2 ). Findings suggest that SM may be related to social phobia, 3 with anxiolytic medications and psychotherapy having been examined. Medication studies included a randomized controlled trial of fluoxetine 4 with some open trials of other serotonergic medications, and numerous case reports. Follow-up intervals were relatively brief (9 to 12 weeks), and it is unclear whether samples in these trials were representative of children with SM in the general population. Psychotherapy studies consist mostly of case reports, with only one small controlled trial of behavioural intervention 5 and no gold standard therapy in the field.
No studies have contrasted outcomes for different treatments. Given the high persistence rates of SM and associated morbidity, 6 comparative trials are needed to guide clinicians' interventions and improve the chances of returning such children to a normative developmental course. This pilot study is a first step toward such trials.
Methods
In our study, 20 children with SM and their parents, participants in a study of cognitive and linguistic abilities in SM at a children's hospital, were invited to return 6 to 8 months after their initial research assessment. 7 When assessed initially, all children had been mute for at least one full school year. All procedures were approved by the Research Ethics Board of the Hospital for Sick Children in Toronto, and parents provided written informed consent. Verbal assent was obtained from children whenever possible.
At follow-up, treatment received was determined and outcomes were measured using brief parent-report questionnaires (SMQ 8 and CGI 9 ) and a semi-structured parent interview (Anxiety Disorders Interview Schedule 10 ) administered by a trained child psychiatrist blind to treatment status. This psychiatrist also completed the CGAS 11 based on the interview and clinical notes on current functioning for each child. The SMQ ascertains quantity of speech in 3 environments: family, school, and other social situations, and has been used in numerous research studies of SM. In this study, both the total score and the sum of the 2 nonfamilial environment scores were related to treatment, as children with SM often speak normally at home. Treatment was determined largely by parental preference, with no attempt to assign children to particular treatments apart from providing school consultations to all participants. Monitoring of treatment was left to clinicians' judgment, as would be the case in community settings.
Results
Among the original 20 subjects seen, 17 returned for a 6-to 8-month follow-up appointment (85%) with at least one parent. All mothers attended, so results are by maternal report. Nonparticipants did not differ from participants in demographic characteristics or initial CGAS or SMQ scores, suggesting the follow-up sample was representative of the original. Similarly, demographic characteristics, initial CGAS, and initial SMQ did not differ for medicated, compared with unmedicated children, nor for those who did, compared with those who did not receive psychotherapy. The 17 participants had a mean age of 7.83 (SD 1.28) years at initial assessment (that is, 8.33 years at follow-up). Twelve were female and 5 were male, showing a trend towards female preponderance (÷ 2 = 2.88, P = 0.09). All but one initially met criteria for both SM and social phobia on parental interview (Anxiety Disorders Interview Schedule). The remaining child only met criteria for SM.
Diagnoses remained stable over 6 to 8 months, with the exception of one child who no longer met criteria for SM at follow-up.
Significant changes in CGAS or SMQ over 6 to 8 months were examined for all 17 children using paired sample t tests ( Table 1 ). Significant improvements were found in the CGAS (t = 3.49, P = 0.003), the total SMQ (t = 3.45, P = 0.004), and the SMQ school and other scales (t = 3.40, P = 0.004). Significance was maintained when applying the Bonferroni correction for multiple t tests. Global improvement ratings by mothers averaged 3 for the sample, corresponding to improved.
All children's schools received monthly telephone consultations from an experienced member of the clinical research team. All children were initially medication-free, but were offered treatment with an SSRI at time of assessment. Ten of the 17 families agreed to such treatment. Eight children received a liquid preparation of fluoxetine, and 2 received sertraline. Dosage was titrated upwards gradually depending on response, with final dosages of 10 to 25 mg of fluoxetine and 25 to 50 mg sertraline. Three families admitted providing the medication inconsistently to their child (stopping it without the physician's knowledge in one case), though no formal measures of compliance were done. Insomnia was reported in one child on fluoxetine, but responded to dosage reduction. No other medication side effects were reported.
Psychotherapy or speech therapy was not offered at assessment owing to resource constraints, but 10 families obtained such therapy privately for their children (5 with a speech therapist; 5 with a psychologist). The average number of sessions was 9.20 (SD 2.93). Overall, there were 4 children who received both interventions, 6 children who received medication only, 6 children who received therapy only, and one child who received neither. A medication´therapy chi-square was not significant (that is, children were not more or less likely to receive one modality based on receiving the other).
Repeated measures ANOVAs were done to determine any 6to 8-month outcome differences in children receiving medical or nonmedical intervention (Table 1 ). Owing to sample size constraints, specific medications and specific types of therapy could not be examined separately. As mentioned, there were significant improvements with time in the CGAS, total SMQ, and sum of the SMQ school and other subscales. There were also significant medication´time interactions for the CGAS (F = 9.58; df = 1,14; P = 0.007) and the SMQ school and other scales (F = 6.24; df = 1,14; P = 0.028), with medicated children showing greater improvements than unmedicated children. There was no such interaction for the total SMQ. There were no significant therapy´time interactions, though there was a trend toward greater CGAS improvement for children that did not receive therapy (F = 3.85; df = 1,14; P = 0.07).
Maternal Global Improvement ratings were compared by intervention modality using t tests. Medicated children showed significantly greater improvement than unmedicated children (t = 2.23, P = 0.04). There was no significant difference related to nonmedical intervention.
Discussion
In this clinical sample of children with severe SM, improvements were evident by clinician and maternal report after 6 to 8 months, but most children still met criteria for SM. This is consistent with previous reports of high persistence rates in clinical samples. 6 Choice of interventions might have been influenced by selection biases including financial circumstances, parental education, and child severity. Nevertheless, by maternal report, using serotonergic medications increased the child's degree of overall improvement and reduced mutism outside the home. Clinicians also rated medically treated children as showing higher functional gains than nonmedicated children. Previous efficacy trials of fluoxetine in SM showed similar outcomes. 4, 12 Interestingly, medication-related gains occurred despite noncompliance in some cases and a lack of the rigorous medication monitoring typical of efficacy trials. This finding suggests potential effectiveness for SSRIs in treating SM in real-world environments. The follow-up interval (6 to 8 months) is also more typical in community use of SSRIs than in short-term efficacy studies. Further medication effectiveness studies are indicated, though, especially as children did not all receive the same SSRI, and SM may respond differently to different SSRIs. Because all children in this sample received school consultations regarding the management of SM, we also cannot conclude that improvement was due to medication alone. The possible benefits of such consultations, alone or in combination with medication, warrant further study.
Psychotherapy and speech therapy did not appear to affect outcomes, except for a trend toward greater CGAS improvements in the absence of therapy. interpret. For example, it is possible that highly trained therapists using a manualized treatment might have obtained more encouraging results. The diversity of nonmedical treatment approaches received, however, speaks to the lack of a gold standard therapy for SM and the need to further develop and evaluate potentially useful therapies. The sample was too small to determine if combining medication and therapy would be more helpful than doing either alone.
Conclusions
Despite the significant limitations of this preliminary, nonrandomized study and recent controversy surrounding the use of SSRIs in children, 13 the findings suggest a potential benefit to using serotonergic medications in children with persistent SM. Randomized effectiveness trials that include long-term follow-up would further elucidate using SSRIs in this population, alone or in combination with other interventions. Support was not found for non-medical interventions apart from (possibly) school consultation, but standardized nonmedical interventions or treatment packages that include medical and nonmedical components await further development and evaluation.
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